As Bertagnolli steps in, NIH and FDA reenvision clinical trials and evidence generation

Steven Libutti tells us about building a $900 million cancer hospital for Rutgers RWJBarnabas Health

Over the past seven years, as Steven K. Libutti was designing the 12-story, $900-plus million cancer hospital in New Brunswick, NJ, he often thought of the functionality of the building that inspired it: Building 10, the NIH Clinical Center.

Makary vows to speed up drug approvals and end FDA’s “cozy” relationship with industry
Commissioner promises to protect scientific integrity while bringing in “fresh” MAHA ideas

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models.

April 25, 2025

Vol.51 No.16

By Claire Marie Porter

Cancer Policy

HHS said it would terminate Women’s Health Initiative, then reconsidered

On April 21, Women’s Health Initiative investigators were informed that HHS would be terminating the WHI Regional Center contracts at the end of the current fiscal year.

April 25, 2025

Vol.51 No.16

By Jacquelyn Cobb and Claire Marie Porter

Cancer Policy

ASCO seeks to engage new leaders of NIH, CMS, and FDA

The Association for Clinical Oncology has reached out to the new leaders of federal health agencies to ensure continued progress in cancer care, research, and patient access, the organization said.

FDA’s Richard Pazdur to receive the 2025 AACR Enduring Impact Award for transformative service to cancer science and medicine

The 2025 AACR Enduring Impact Award for Transformative Service to Cancer Science and Medicine will be presented to FDA’s Richard Pazdur during the AACR Annual Meeting 2025, to be held April 25-30 at the McCormick Place Convention Center in Chicago.

April 25, 2025

Vol.51 No.16

In Brief

Swim Across America grants $900,000 toward gene editing innovation

Joseph FraiettaPietro GenoveseSwim Across America, the nonprofit funding innovative clinical trials and patient-centered programs for cancer, awarded $450,000 grants to two of its beneficiaries, Alliance for Cancer Gene Therapy and Dana-Farber Cancer Institute, to support the work of novel gene and base editing techniques used in advanced cancer research, including targeted therapies, immunotherapies, and cellular therapies.

April 25, 2025

Vol.51 No.16

As Bertagnolli steps in, NIH and FDA reenvision clinical trials and evidence generation

YOU MAY BE INTERESTED IN

Steven Libutti tells us about building a $900 million cancer hospital for Rutgers RWJBarnabas Health

Makary vows to speed up drug approvals and end FDA’s “cozy” relationship with industry
Commissioner promises to protect scientific integrity while bringing in “fresh” MAHA ideas

HHS said it would terminate Women’s Health Initiative, then reconsidered

ASCO seeks to engage new leaders of NIH, CMS, and FDA

FDA’s Richard Pazdur to receive the 2025 AACR Enduring Impact Award for transformative service to cancer science and medicine

Swim Across America grants $900,000 toward gene editing innovation

Renew today!

Subscriber content

Never miss an issue!

Login

As Bertagnolli steps in, NIH and FDA reenvision clinical trials and evidence generation

YOU MAY BE INTERESTED IN

Steven Libutti tells us about building a $900 million cancer hospital for Rutgers RWJBarnabas Health

Makary vows to speed up drug approvals and end FDA’s “cozy” relationship with industryCommissioner promises to protect scientific integrity while bringing in “fresh” MAHA ideas

HHS said it would terminate Women’s Health Initiative, then reconsidered

ASCO seeks to engage new leaders of NIH, CMS, and FDA

FDA’s Richard Pazdur to receive the 2025 AACR Enduring Impact Award for transformative service to cancer science and medicine

Swim Across America grants $900,000 toward gene editing innovation

Never miss an issue!

Login

Makary vows to speed up drug approvals and end FDA’s “cozy” relationship with industry
Commissioner promises to protect scientific integrity while bringing in “fresh” MAHA ideas